ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Ken Shinomiya Becomes Leader of Asahi Kasei’s Healthcare Sector

Leading the way for the sector’s continued growth and commitment to improving patient outcomes

Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of its Healthcare Sector succeeding Richard Packer. Under Shinomiya, Asahi Kasei’s Healthcare Sector will further advance its portfolio and global presence of pharmaceuticals, life science, and critical care products and services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424681712/en/

Ken Shinomiya, Leader of Asahi Kasei’s Healthcare Sector

Ken Shinomiya, Leader of Asahi Kasei’s Healthcare Sector

Having served as Vice President of Strategy at ZOLL Medical Corporation from fiscal 2016 to fiscal 2017, Shinomiya became Head of the Bioprocess Division of Asahi Kasei Medical in April 2019 and President of Asahi Kasei Medical in April 2023. In April 2025, he was named President of Asahi Kasei Life Science, the successor company to the bioprocess business of Asahi Kasei Medical. With operations focused on products and services that support the manufacture of pharmaceuticals, the life science business has grown globally by ascertaining market needs and business opportunities within the pharmaceutical industry. Under Shinomiya’s leadership, the life science business has successfully expanded from its foundational Planova™ virus removal filters through the addition of contract research organization (CRO) testing services as well as the biologics contract development and manufacturing organization (CDMO) business of Bionova Scientific in the U.S.

Asahi Kasei’s Healthcare Sector has dramatically globalized since the 2012 acquisition of ZOLL Medical Corporation with its U.S.-based business platform in critical care. Since then, the Healthcare Sector has accelerated its growth strategy as a diverse global healthcare company by accurately discerning market needs, making proactive investments including M&A, and moving its headquarters to the U.S. in 2023. This has leveraged the strength of Asahi Kasei’s Healthcare business while enhancing global management.

Under the new leadership, the Healthcare Sector will continue to execute a long-term strategy to grow its pharmaceutical, life science, and critical care businesses. Guided by its mission to “Improve and save patients’ lives,” the sector is committed to delivering innovative therapeutics and medical devices that address unmet medical needs and contribute to better patient outcomes worldwide. It will serve as the main growth driver of the Asahi Kasei Group, targeting operating income of ¥150 billion in 2030.

“For over a century, the Asahi Kasei Group has created distinctive business models leveraging creativity and innovation to provide exceptional products and services to the world,” said Ken Shinomiya, Leader of Asahi Kasei’s Healthcare Sector. “Our healthcare business exemplifies Asahi Kasei’s unique ability to effectively integrate the advanced, efficiency-oriented management approaches gained through global acquisitions. Moving forward, we will further evolve based on our blended international outlook as we continue to lead the growth and globalization of the Asahi Kasei Group.”

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Healthcare. Its Healthcare operations include devices and systems for critical care, products and services for the manufacture of biotherapeutics, and a growing portfolio of specialty pharmaceuticals. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.11
-3.99 (-1.60%)
AAPL  274.10
-1.15 (-0.42%)
AMD  257.98
+20.46 (8.62%)
BAC  54.27
+0.64 (1.20%)
GOOG  285.88
-5.86 (-2.01%)
META  611.86
-15.22 (-2.43%)
MSFT  500.87
-7.81 (-1.54%)
NVDA  192.10
-1.06 (-0.55%)
ORCL  228.18
-7.97 (-3.38%)
TSLA  430.22
-9.40 (-2.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.